Acronym:
UNISoN
ACTRN/NCT /ethics:
Ethics: 316.17
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | Kidney | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II | Tumour Stream | Kidney |
| Age Range | 18 years and older | Cancer Stage | Metastatic or Widespread |
| Sex | Both | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Kidney |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Kidney |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
Phase II sequential treatment trial of single agent nivolumab, then combination Ipilimumab + nivolumab in metastatic or unresectable non-clear cell renal cell carcinoma.
Lay Summary
Sponsor / Cooperative group
ANZUP
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Ashford Cancer Centre Research | Helen Daykin | hdaykin@adelaidecancercentre.com.au | 08 8292 2240 | Recruiting | |
| Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Ganessan Kichenadasse | Recruiting |